Contrasting LiveRamp (NYSE:RAMP) and CompuMed (OTCMKTS:CMPD)

CompuMed (OTCMKTS:CMPD) and LiveRamp (NYSE:RAMP) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Valuation and Earnings

This table compares CompuMed and LiveRamp”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CompuMed	$5.84 million	0.89	-$30,000.00	$0.11	35.82
LiveRamp	$707.17 million	2.83	$11.88 million	$0.05	614.20

LiveRamp has higher revenue and earnings than CompuMed. CompuMed is trading at a lower price-to-earnings ratio than LiveRamp, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

CompuMed has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, LiveRamp has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.

Institutional and Insider Ownership

93.8% of LiveRamp shares are owned by institutional investors. 22.0% of CompuMed shares are owned by insiders. Comparatively, 3.4% of LiveRamp shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares CompuMed and LiveRamp’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CompuMed	2.37%	4.54%	3.27%
LiveRamp	0.40%	1.25%	0.98%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for CompuMed and LiveRamp, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CompuMed	0	0	0	0	0.00
LiveRamp	0	1	6	0	2.86

LiveRamp has a consensus price target of $41.14, indicating a potential upside of 33.97%. Given LiveRamp’s stronger consensus rating and higher possible upside, analysts clearly believe LiveRamp is more favorable than CompuMed.

Summary

LiveRamp beats CompuMed on 9 of the 14 factors compared between the two stocks.

About CompuMed

CompuMed, Inc., an enterprise telemedicine solutions company, provides clinical care services for patients and medical facilities. It offers telecardiology and teleradiology services that provide real-time access to U.S. Board-Certified specialists through cloud-based technology and integrated medical devices to medical facilities worldwide. The company also provides enterprise telemedicine solutions; a suite of telecardiology services and diagnostic exam interpretations for pediatric and adult patients, including electrocardiogram (ECG) devices, echocardiogram, ECG, vascular, holter, nuclear, and video consults; and reading, transcription, reporting, storage, and video consultations in the areas of Vscan, X-ray, ultrasound, mammography, computed tomography, magnetic resonance imaging, and radiologist video consults. It also offers OsteoGram software that works in combination with standard or digital X-ray equipment to support osteoporosis screening, diagnosis, and therapy monitoring. In addition, the company provides mobile ECG and ultrasound solutions that provide patients with immediate access to its board-certified specialists; and medical devices. It serves organ procurement organizations, rural healthcare, and correctional healthcare industries. CompuMed, Inc. was founded in 1973 and is headquartered in Los Angeles, California.

About LiveRamp

LiveRamp Holdings, Inc., a technology company, operates a data collaboration platform in the United States, Europe, the Asia-Pacific, and internationally. The company operates LiveRamp Data Collaboration platform enables an organization to unify customer and prospect data to build a single view of the customer in a way that protects consumer privacy. Its platform supports various people-based marketing solutions, including data collaboration, activation, measurement and analytics, identity, and data marketplace. The company sells its solutions to enterprise marketers, agencies, marketing technology providers, publishers, and data providers in various industry verticals, such as financial, insurance and investment services, retail, automotive, telecommunications, high tech, consumer packaged goods, healthcare, travel, entertainment, and non-profit. The company was formerly known as Acxiom Holdings, Inc. and changed its name to LiveRamp Holdings, Inc. in October 2018. The company was incorporated in 2018 and is headquartered in San Francisco, California.